ATE277012T1 - Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress - Google Patents

Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress

Info

Publication number
ATE277012T1
ATE277012T1 AT99945671T AT99945671T ATE277012T1 AT E277012 T1 ATE277012 T1 AT E277012T1 AT 99945671 T AT99945671 T AT 99945671T AT 99945671 T AT99945671 T AT 99945671T AT E277012 T1 ATE277012 T1 AT E277012T1
Authority
AT
Austria
Prior art keywords
treatment
donor
stress
piperidine
nitrogen oxide
Prior art date
Application number
AT99945671T
Other languages
English (en)
Inventor
Erik Emil Aenggard
Abdullah Ibrahim Haj-Yehia
Original Assignee
Oxon Medica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxon Medica Inc filed Critical Oxon Medica Inc
Application granted granted Critical
Publication of ATE277012T1 publication Critical patent/ATE277012T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
AT99945671T 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress ATE277012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9801398.0A GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds
PCT/GB1999/000231 WO1999037616A1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress

Publications (1)

Publication Number Publication Date
ATE277012T1 true ATE277012T1 (de) 2004-10-15

Family

ID=10825732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99945671T ATE277012T1 (de) 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress

Country Status (9)

Country Link
US (3) US6448267B1 (de)
EP (1) EP1124801B1 (de)
JP (1) JP2002501049A (de)
AT (1) ATE277012T1 (de)
AU (1) AU4120699A (de)
CA (1) CA2318208C (de)
DE (1) DE69920496T2 (de)
GB (1) GB9801398D0 (de)
WO (1) WO1999037616A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
JP2003532622A (ja) * 1999-06-14 2003-11-05 ヘンリー フォード ヘルス システム 神経発生を誘導する一酸化窒素ドナー
KR20010038797A (ko) * 1999-10-27 2001-05-15 김길환 홍국을 이용한 일산화질소 생성제 조성물 및 이를 이용한 약품 조성물
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
YU12703A (sh) * 2000-08-22 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Farmaceutska kombinacija antagonista angiotenzina ii i inhibitora angiotenzin i konvertujućeg enzima
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
EP1353655A2 (de) * 2001-01-26 2003-10-22 Metaphore Pharmaceuticals Inc. Verfahren zur behandlung von neurodegenerativen erkrankungen mit pentaaza-makrozyklischen ligandkomplexen
US20020151431A1 (en) * 2001-01-26 2002-10-17 Jeff Thornton Recovery method
US20030045461A1 (en) 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
WO2003053425A1 (en) * 2001-12-10 2003-07-03 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
US7378438B2 (en) 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
AU2003278565A1 (en) * 2002-10-25 2004-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
WO2004078172A2 (en) * 2003-03-06 2004-09-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
CA2556967A1 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
WO2005102282A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
AU2005250056A1 (en) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents and methods for diagnosing stress
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
WO2006084041A2 (en) 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing diabetes
WO2006084200A2 (en) * 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing cardiovascular disease
US20090042819A1 (en) * 2005-02-16 2009-02-12 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
EP1888510A4 (de) 2005-05-27 2013-01-16 Univ North Carolina Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
EP1933845A2 (de) 2005-08-25 2008-06-25 Medtronic Vascular, Inc. Stickoxid freisetzende biologisch abbaubare polymere als medizinprodukte und beschichtungen dafür
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
MX2008014396A (es) * 2006-05-11 2009-02-06 Textron Innovations Inc Dispositivo y metodo para reparar componentes estructurales.
US7985594B2 (en) * 2006-05-12 2011-07-26 Massachusetts Institute Of Technology Biradical polarizing agents for dynamic nuclear polarization
WO2007134160A2 (en) * 2006-05-12 2007-11-22 Massachusetts Institute Of Technology Temperature-jump dynamic nuclear polarization
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
JP5191702B2 (ja) * 2006-08-01 2013-05-08 三菱レイヨン株式会社 N−オキシル化合物、その製造方法および重合防止方法
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US20120245080A1 (en) 2009-04-15 2012-09-27 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
BRPI0925099A2 (pt) 2009-06-24 2018-10-16 Strategic Science & Tech Llc composição tópica contendo ibuprofeno
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
EP2528601A1 (de) * 2010-01-26 2012-12-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Zusammensetzungen und verfahren zur prävention und behandlung von lungenhochdruck
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
JP2014504592A (ja) 2010-12-29 2014-02-24 ストラテジック サイエンス アンド テクノロジーズ, エルエルシー 勃起不全および他の適応症の処置
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
EP2681286B1 (de) 2011-02-28 2018-08-15 Novan, Inc. Stickoxid-freisetzende s-nitrosothiol-modifizierte kieselsäureteilchen und verfahren zu ihrer herstellung
WO2013005216A1 (en) * 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
US8715621B2 (en) 2012-03-15 2014-05-06 Massachusetts Institute Of Technology Radical polarizing agents for dynamic nuclear polarization
US20150368197A1 (en) 2012-06-21 2015-12-24 Radikal Therapeutics Ins. Compositions and methods for treatment of inflammatory diseases of the lung
US9604932B2 (en) 2013-03-05 2017-03-28 Radikal Therapeutics Inc. Substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds for treating diseases associated with oxidative stress or endothelial dysfunction
CN107847484B (zh) * 2015-03-26 2021-07-06 耶路撒冷希伯来大学伊森姆研究发展公司 用于治疗呼吸道疾病的硝基氧自由基
CA3204594A1 (en) 2020-12-15 2022-06-23 Life Technologies Corporation Chemically defined serum albumin substitutes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752812A (en) 1970-02-05 1973-08-14 Pfizer 2-trifluoromethylquinoxalinedi n oxides
US4563446A (en) 1983-07-27 1986-01-07 Takeda Chemical Industries, Ltd. Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
DE3328365A1 (de) * 1983-08-03 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Neue diagnostische mittel
US5352442A (en) 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5890387A (en) 1989-08-24 1999-04-06 Aquaform Inc. Apparatus and method for forming and hydropiercing a tubular frame member
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
CA2173582C (en) 1993-10-06 2006-11-28 Piero Del Soldato Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US6140309A (en) 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5885842A (en) 1996-11-08 1999-03-23 Medinox, Inc. Methods for the detection of nitric oxide in fluid media
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
JP3377731B2 (ja) * 1997-09-29 2003-02-17 三菱重工業株式会社 高性能水素分離膜
AU2662799A (en) 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (de) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
EP1114048A1 (de) 1998-09-16 2001-07-11 Agnès Bombrun Carbolin-derivate als cgmp phosphodiesterase-inhibitoren
AU775388B2 (en) 1998-11-25 2004-07-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
CZ20012113A3 (cs) 1998-12-14 2001-11-14 Cellegy Pharmaceuticals, Inc. Prostředky a způsoby pro léčbu onemocnění anorektální oblasti
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
BR0012793A (pt) 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide

Also Published As

Publication number Publication date
DE69920496T2 (de) 2005-08-25
US6455542B1 (en) 2002-09-24
AU4120699A (en) 1999-08-09
JP2002501049A (ja) 2002-01-15
CA2318208C (en) 2009-09-29
EP1124801B1 (de) 2004-09-22
US20030069429A1 (en) 2003-04-10
US20020091266A1 (en) 2002-07-11
EP1124801A1 (de) 2001-08-22
DE69920496D1 (de) 2004-10-28
CA2318208A1 (en) 1999-07-29
US6448267B1 (en) 2002-09-10
GB9801398D0 (en) 1998-03-18
US6759430B2 (en) 2004-07-06
WO1999037616A1 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
ATE277012T1 (de) Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
MY119820A (en) Guanidine mimics as factor xa inhibitors
PE74399A1 (es) Combinaciones para diabetes de sulfonilurea - glitazona
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
ATE229001T1 (de) Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
EA200300792A1 (ru) Хиназолины в качестве ингибиторов ммр-13
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
IL150650A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
CO5031285A1 (es) Triarilimidazoles
UA35574C2 (uk) Похідні заміщеної гетероциклом фенілциклогексанкарбонової кислоти, суміші їх ізомерів або окремі ізомери та їх солі
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
DE69313051D1 (de) Ethanolamin-derivate mit sympathomimetischer und anti-pollakiuria wirkung
IL140070A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
DE69526917D1 (de) Anthracyclinon-derivate und ihre verwendung in amyloidose
DK0882726T3 (da) Carbazolcarboxamider som 5-HT1F-agonister
DE60220997D1 (de) N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
NO982505L (no) Sammensetning og fremgangsmÕte for avsvovling av gassformige eller flytende hydrokarboner, vandige systemer og blandinger derav
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DE69119282T2 (de) Aminobenzolverbindungen, Herstellung und Verwendung
ATE95815T1 (de) Mittel zum schutz von pflanzen gegen krankheiten.
DE69312849T2 (de) Mercapto-acetamid-derivate
DE60137352D1 (de) Nsalze, verfahren zur herstellung von beiden und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties